19 October-1 December 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
Channel 1
OA-31-TB epidemiology
event_note
Loading...
query_builder 16:30 - 17:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-31-TB epidemiology
*Please scroll down for more information*


16:30 - 16:35: Introduction


16:35 - 16:43: OA-31-688-23-Estimating the proportion of subclinical TB disease: definitions, associations and screening A significant proportion of the global tuberculosis (TB) burden is subclinical, it is not detectable by current symptom-based screening efforts and is fueling the TB epidemic through continued Mycobacterium tuberculosis transmission. We extracted data from TB prevalence surveys conducted since 1990 and our results revealed the potential of changing TB case finding policies.

Beatrice Frascella

16:43 - 16:51: OA-31-689-23-A high-resolution snapshot of subclinical TB via community-wide sputum testing in an urban Ugandan community We performed population-wide, community-based tuberculosis (TB) testing with sputum Xpert MTB/RIF Ultra for >12,000 adults within a two km2 area, in Kampala, Uganda. We compared clinical and bacteriologic characteristics of individuals with undiagnosed TB, to patients diagnosed through routine care at local health facilities, and also to representative TB-negative community members.

Emily Kendall

16:51 - 16:59: OA-31-690-23-Methods and challenges of national TB prevalence surveys in Asia and sub-Saharan Africa: a systematic review This systematic review characterised the methodological challenges of 28 national TB prevalence surveys in Asia and sub-Saharan Africa. Challenges included under-recruitment, under-representation of risk groups, diagnostic reliance on smear as well as logistical constraints including staffing, security and paper-based tools. Solutions included improved funding, political commitment, context-specific diagnostic algorithms and social mobilisation.

Gokul Mishra

16:59 - 17:07: OA-31-691-23-Trends in molecular epidemiology of drug-resistant TB in Estonia Estonia is on the list of 18 high-priority countries for tuberculosis (TB) control that bear 85% of the TB burden and 99% of the multidrug-resistant-TB burden. The study aimed to characterise Mycobacterium tuberculosis isolates, obtained at different time points in Estonia, to assess trends in evolution of drug-resistant TB.

Igor Mokrousov

17:07 - 17:15: OA-31-692-23-Comparing the epidemiology and clinical characteristics of childhood TB through active and passive case finding Most high prevalence areas perform only passive case finding (PCF) for tuberculosis (TB), evaluating children presenting with significant symptoms, rather than active case finding (ACF) through contact tracing. We compared clinical, radiographic and microbiological characteristics of children diagnosed through ACF and PCF and found important differences that impact recognition and care.

Saki Ikeda

17:15 - 17:23: OA-31-693-23-Increasing TB incidence rates and inequitable treatment outcomes for young people with TB in Brazil: a national retrospective cohort study We conducted a national retrospective cohort study in Brazil between 2015-2018 of 42,291 young people newly diagnosed with TB. We found increasing tuberculosis (TB) incidence in young people and those with homelessness, HIV/AIDS, illicit drug use or identifying with black or brown skin colour, were more likely to have unfavourable treatment outcomes.

Louisa Chenciner

17:23 - 17:50: Q&A


Loading...
Channel 3
SP-37-Strategies for addressing barriers for LGBTQIA in accessing high quality TB care: a comparative analysis with HIV
event_note
Loading...
query_builder 16:45 - 17:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-37-Strategies for addressing barriers for LGBTQIA in accessing high quality TB care: a comparative analysis with HIV
*Please scroll down for more information*
A key gap in tuberculosis (TB) strategies globally has been a lack of attention to LGBTQIA populations. Given that the LGBTQIA community is marginalised, at a higher risk of HIV, more likely to have unstable income, food insecurity and poor housing, it also puts them at higher risk of TB. Combining lived experiences, participative approaches and experiences of HIV care across the UK, South Africa and India, this session examines the inherent barriers and exclusion LGBTQI persons face, and how these act as a barrier to accessing care. It draws lessons from these cross country experiences to address these in TB care.

16:45 - 16:50: Introduction

16:50 - 17:03: Barriers LGBTQIA persons face in accessing HIV care: lessons for TBThis presentation will identify the barriers faced by LGBTQIA in accessing HIV care and examine why these barriers exist. It will also throw light on the systemic exclusion of LGBTQIA persons from programmes meant for them. It will identify clear systemic barriers and challenges and how these affect the health and wellbeing of these populations. It will also examine how to address these barriers and exclusion in the context of tuberculosis care. 
Gautam Yadav

17:03 - 17:16: Why those at risk need to define the care they need: lessons on inclusion for health systems from HIV for TB careThis presentation will discuss the impact of excluding LGBTQIA persons from the framing of healthcare policies and interventions. It will explain why inclusion by health systems is necessary. It will then examine the best practices and gaps in the health system in bringing about inclusion of LGBTQIA persons in defining HIV care in diverse countries. Contrasting these experiences, and also outcomes, it will then draw lessons to see how health systems can make the framing of future tuberculosis (TB) care interventions and the implementation of current TB care interventions more inclusive.
Rudrani Chettri

17:16 - 17:29: A health systems and medical perspective on providing HIV care to LGBTQIA persons and the lessons for TBThis presentation will identify the gaps in the health system that create challenges for doctors in providing quality HIV care to LGBTQIA persons. It will talk about the impact of medical abuse on LGBTQIA persons. It will look at how the health system address the medical abuse faced by LGBTQIA persons. It will examine, by drawing lessons from the HIV experience for tuberculosis (TB) care, the role of health systems, medical community and sensitisation in providing quality care to LGBTQIA affected by TB. 




Anastacia Tomson

17:29 - 17:42: The Indian and South African experience of legal activism on LGBTQIA right to health: lessons for TB careThis presentation will examine the role of legal activism in securing a better realisation of the right to health and resulting better quality care for LGBTQIA persons. It will engage in a comparative analysis of current, and previous efforts, in legal activism on LGBTQIA right to health and quality in India and South Africa in contexts such as HIV, identifying the gaps, challenges and best practices. It will conclude by drawing lessons for making tuberculosis (TB) care more inclusive and effective in addressing rights-based barriers to health for LGBTQIA persons, especially in high burden TB countries.
Jayna Kothari

Loading...
Channel 7
TBS3C-The detection of genetic variants associated with antibiotic tolerance, persistence and drug resistance: panel discussion
event_note
Loading...
query_builder 17:20 - 18:05 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS3C-The detection of genetic variants associated with antibiotic tolerance, persistence and drug resistance: panel discussion
*Please scroll down for more information*
Multiple active anti-mycobaterial drugs are required to cure tuberculosis. Monotherapy or treatment with insufficient active drugs accelerates the development of mycobacterial resistance resulting in treatment failures and, ultimately, undermining elimination strategies. For this reason, understanding the detailed mechanisms of resistance, as well as interactions between the host and different drugs, is important as it allows in vivo activity to be predicted. This session aims to discuss recent findings with respect to our understanding of anti-mycobacterial drug resistance and the prediction of susceptibility, notably based on genome sequence data.

17:20 - 17:45: Panel discussion

Maha Farhat
Thomas Dick
Sarah Fortune
Timothy Rodwell

17:45 - 18:05: Live Q&A

Maha Farhat
Thomas Dick
Sarah Fortune
Timothy Rodwell

Loading...
Channel 1
CANCELLED - Member-only ‘Meet the Expert’ session
event_note
Loading...
query_builder 18:15 - 19:15 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session
card_travel Meet the expert session
mic English
CANCELLED - Member-only ‘Meet the Expert’ session
Members will have the unique opportunity at the 51st Union World Conference on Lung Health to participate in a member-only Q&A session with fundraising expert, Erik Detiger.
Erik is the founder of Philantropia, an independent consultancy specialised in international fundraising and philanthropy. He has a wealth of first-hand knowledge and expertise on what it takes to successfully raise funds.

Join this 60-minute virtual ‘Meet the Expert’ session to find out: How to find donors and build a list of great prospective donorsHow to network with donorsHow to deal with donors that do not accept unsolicited proposalsHow to write great concept notes and proposals; and any other questions you may have.

18:15 - 18:25: Answering your questions about how to fundraise

Erik Detiger
 
Loading...
Channel 3
MTE-08-Meet the expert: Adult and Child Lung Health
event_note
Loading...
query_builder 18:15 - 19:15 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Meet the expert session
mic English
MTE-08-Meet the expert: Adult and Child Lung Health
*Please scroll down for more information*
Clinical management of COVID-19
Please note that the number of participants is limited to 50 for this session.

Loading...
Channel 4
MTE-09-Meet the expert session: Zoonotic TB
event_note
Loading...
query_builder 18:15 - 19:15 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Meet the expert session
mic English
MTE-09-Meet the expert session: Zoonotic TB
*Please scroll down for more information*
Global Epidemics and Pandemics resulting from Zoonotic Diseases: The role of the OIE

Please note that the number of participants is limited to 50 for this session.

18:15 - 19:15: Global epidemics and pandemics resulting from zoonotic diseases: the role of the World Organisation for Animal Health


Loading...
Channel 2
SS-09-Testing to turn the COVID-19 pandemic: the opportunity for TB
event_note
Loading...
query_builder 18:15 - 19:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-09-Testing to turn the COVID-19 pandemic: the opportunity for TB
*Please scroll down for more information*
Organised by: FIND and The Global Fund to Fight AIDS, Tuberculosis and Malaria.
FIND and The Global Fund are co-convenors of the Access to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar – part of a  global collaboration to accelerate the development, production and equitable access to new COVID-19 tools including diagnostics. In addition  to developing new tests, the ACT Accelerator Diagnostics Pillar aims to strengthen low- and middle-income countries’ ability to procure, import, distribute tests  and manage data to assist governments in decision making. Tests developed to enable rapid diagnosis of tuberculosis (TB) are now being  used to diagnose COVID-19. Could global diagnostic networks and new COVID-19 tools be utilised to combat TB in the future?

18:15 - 18:19: Introduction


18:19 - 18:53: Panel discussion: TB, COVID-19 and ACT-A Dx – mitigating the impact and protecting TB gains Diagnostics are critical to any health response and essential to limit the spread of disease. However, greater innovation and  funding are needed to ensure tests can be deployed quickly and easily to everyone who needs one. In deploying new tools, programmes must  aim for integrated service delivery to balance supply and deployment constraints. FIND and The Global Fund are co-convenors of the Access  to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar under which 50 new diagnostic tests have been evaluated. A new rapid antigen test  will soon be ready for roll out and 17 million tests have been delivered to low-and middle-income countries. The ACT-Accelerator experience provides vital lessons on  what a blueprint for successful pandemic preparedness and response could look like for diagnostics. What lessons can we learn for tuberculosis (TB), which is already experiencing the knock-on impact of COVID-19, and how do we protect our gains in TB while successfully beating the pandemic?

Catharina Boehme
John Nkengasong
Kuldeep Singh Sachdeva
Peter Sands

18:53 - 19:03: TB tests being 'repurposed' for COVID-19: experience with Truenat, GeneXpert, digital X-rays and next-generation  sequencing The COVID-19 pandemic has seen existing diagnostics for tuberculosis (TB) being repurposed or used to diagnose COVID-19. Cepheid  Inc’s GeneXpert® MTB/RIF - for the rapid diagnosis of TB and detection of rifampicin-resistance - is being used to run a newly developed  COVID-19 test. Similarly, Indian diagnostic manufacturer, Molbio, whose Truenat™ test was recently endorsed by the World Health Organization received approval  from India’s regulatory authority for a Truenat COVID-19 test, expanding the number of existing diagnostics platforms repurposed for COVID-19. Additionally, digital chest Xray can be deployed along with artificial intelligence-based tools for both TB and COVID-19.  Leveraging ongoing efforts in enabling next-generation sequencing solutions for drug-resistant TB detection under the Unitaid-funded  Seq&Treat project, FIND has compiled a landscape and a preliminary assessment of sequencing utility and capacity in low-and middle-income countries for COVID-19 surveillance and management. We’ll share in-country implementers' experience repurposing TB tests for COVID-19.

Morten Ruhwald

19:03 - 19:13: Ending TB amid the COVID-19 pandemic: a community-led response The COVID-19 pandemic has had tremendous impact on tuberculosis (TB) programmes and activated disruptions along the care spectrum, from screening to diagnosis to the treatment of people with TB. While efforts have been made through the contribution of the Global Fund and stakeholders worldwide, impactful gains were undone. While barriers were being addressed there was an increase in the barriers faced, including  access to services, along with heightened stigma and the dual stigma of COVID-19 and TB. There is a need for meaningful engagement and for strengthening community engagement and linkages in order to address barriers collectively and to find solutions. Community systems and community-led  monitoring can support the implementation of catch-up plans so that efforts in finding the missing people with TB can be reinforced and barriers can be mitigated.
This session highlights experiences of civil society and partners and their role in the mitigation of the impact of COVID-19 on TB and on the road ahead.

Carol Nawina (Nyirenda) Kachenga

19:13 - 19:23: Access to TB diagnostic services during COVID-19: experience from South Africa In many of the countries most heavily affected by HIV, tuberculosis (TB) and malaria, the knock-on impact of COVID-19 on these three  diseases, in terms of incremental deaths, may outweigh the direct impact of the virus. The Global Fund is already witnessing the impact of  COVID-19 on the fight against HIV, TB and malaria across the countries where itinvests. For example, TB laboratory services are under acute  pressure, with 20% experiencing high or very high levels of disruption, with many of the advanced diagnostics instruments put in place to  diagnose TB now being used for testing for COVID-19. We’ll hear from South Africa – a country with a high TB and HIV burden which is now addressing  the deadly pandemic - on scale-up of COVID-19 testing and integration of testing services for COVID-19 and TB.

Wendy Stevens

19:23 - 19:45: Q&A session


Loading...
Community Connect
Adapting TB advocacy in times of COVID-19
event_note
Loading...
query_builder 20:00 - 20:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session
card_travel Community Connect
mic English
Adapting TB advocacy in times of COVID-19
COVID-19 will change the future, but for TB it is taking us back to the past. Global TB incidence could increase to levels we left behind in 2013. Deaths in 2021 are on track to increase to numbers we saw in 2016. This would be nothing short of a tragedy. Much is currently being made about reallocation of already-sparse global health resources to help combat COVID-19. Our healthcare systems are precarious, and COVID-19 is forcing many to make tough choices. We must work toward a future in which those choices don’t have to be made. Equitable and timely access to much needed tools including quality tests is something to which everyone should have the right, so they can get the care they need, whatever the diagnosis. In this session you will hear first-hand from a person affected by TB, along with COVID-19 survivor, and about how TB diagnostic priorities and approaches need to be adapted amid the pandemic. You will also have an opportunity to learn more about and discuss the results and calls to action related to the impact of COVID-19 on TB diagnostics from a recently launched civil society and affected community led global survey. The survey aimed to develop a rich understanding of experiences, challenges and opportunities across regions and key stakeholders, including people with TB, frontline healthcare workers, TB researchers, policy and program officers, and TB advocates. A concerning key finding of the report was a significant decrease in TB testing during the pandemic, and a clear call to action for leveraging investments in COVID-19 testing to strengthen the TB response emerged. In this session we will work together as a community to reflect on on the ground experiences reported and build and advocacy strategy for taking action.

Chair:
Karishma Saran, Strategic Communications Officer, FIND and Secretariat, Stop TB Partnership’s New Diagnostics Working Group

Speakers:
1. Robyn Waite, Results Canada 
2. Saurabh Rane, TB advocate 
3. Nombasa Dumile, frontline health worker 
4. Lwazi Mlaba, COVID-19 Survivor and Living with Long COVID-19
Loading...
Channel 4
MTE-10-Meet the expert session: Europe track
event_note
Loading...
query_builder 09:45 - 10:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Meet the expert session
mic English
MTE-10-Meet the expert session: Europe track
*Please scroll down for more information*
Impact of COVID19 on TB: what is happening in Europe?

Please note that the number of participants is limited to 50 for this session.

Loading...
Channel 5
MTE-11-Meet The Expert session: tobacco control
event_note
Loading...
query_builder 09:45 - 10:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Meet the expert session
mic English
MTE-11-Meet The Expert session: tobacco control
*Please scroll down for more information*
COVID-19 links to smoking under tobacco industry interference

Please note that this is a live session and the number of participants is limited to 50.

Loading...
Processing. Please wait.
Loading...